- Home
- RPAY vs VOR Comparison
RPAY vs VOR Comparison
Compare RPAY & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | VOR |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 345.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RPAY | VOR |
|---|---|---|
| Price | $3.59 | $16.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $6.81 | ★ $64.78 |
| AVG Volume (30 Days) | 673.0K | ★ 1.1M |
| Earning Date | 03-02-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,947,000.00 | N/A |
| Revenue This Year | $0.22 | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.98 | $2.62 |
| 52 Week High | $7.84 | $65.80 |
Technical Indicators
Market Signals| Indicator | RPAY | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 58.27 |
| Support Level | $3.38 | $13.00 |
| Resistance Level | $3.73 | $18.60 |
| Average True Range (ATR) | 0.15 | 1.61 |
| MACD | -0.01 | 0.44 |
| Stochastic Oscillator | 40.20 | 74.37 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.